Post hoc analysis of the phase 3 SOLSTICE trial (211 solid organ transplant recipients with refractory CMV): week-20 mortality was higher in those without CMV clearance at week 8 than in responders (10 deaths vs none; p = 0.0024).
Secondary analysisn = 211
Kamar et al. Association Between Cytomegalovirus Viremia Clearance and Post-Solid Organ Transplant Mortality in Patients With Refractory Cytomegalovirus Infection: SOLSTICE Post Hoc Analysis